WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] => all
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-26 16:35:20
[post_modified_gmt] => 2025-02-26 21:35:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 3248
[post_author] => 3
[post_date] => 2019-01-28 12:55:22
[post_date_gmt] => 2019-01-28 12:55:22
[post_content] => The latest CFB Newsletter has been released - Catch up on client financings, newcos, expansions, and other happenings here.
Be sure to follow us on Twitter, LinkedIn and Facebook for the latest Center news.
[post_title] => Winter 2019 Newsletter
[post_excerpt] => The latest CFB Newsletter has been released - Catch up on client financings, newcos, expansions, and other happenings.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => winter-2019-newsletter
[to_ping] =>
[pinged] =>
[post_modified] => 2019-05-01 12:57:58
[post_modified_gmt] => 2019-05-01 12:57:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3248
[menu_order] => 103
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4032
[post_author] => 4
[post_date] => 2023-03-02 16:46:18
[post_date_gmt] => 2023-03-02 16:46:18
[post_content] =>
A second-generation taxane conjugate in a nanoemulsion formulation (called NE-DHA-SBT-1214) developed by Stony Brook University Distinguished Professor Iwao Ojima in his chemistry laboratory and through the Institute of Chemical Biology & Drug Discovery (ICB&DD) and licensed to Dr. James Egan, has received a $24 million investment to be taken to phase 2a development. Preclinical results have persuaded TVM Capital Life Science to invest in the technology via Recurv Pharma.
The VC fund will invest up to $24 million in Recurv through its project-focused company (PFC) investment objective, an initiative focused on backing first or best-in-class candidates that are clearly differentiated from the competition or add clinical value. Read More on Fierce Pharma and via SBU News.
[post_title] => Anti-Cancer Agent Developed at SBU Shows Great Promise Against Tumors, Receives $24M Investment
[post_excerpt] => TVM Capital Life Science to invest $24M in Recurv Pharma to develop an SBU technology.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => anti-cancer-agent-developed-at-sbu-shows-great-promise-against-tumors-receives-24m-investment
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-22 11:35:16
[post_modified_gmt] => 2024-08-22 15:35:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4032
[menu_order] => 7
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 4074
[post_author] => 4
[post_date] => 2023-04-24 16:22:15
[post_date_gmt] => 2023-04-24 16:22:15
[post_content] =>
The Center for Biotechnology has announced the appointment of Dr. Louis A. Peña as Director of the new Program in Life Sciences Innovation and Entrepreneurship. Additionally, Dr. Peña has been appointed as Associate Professor of Practice in the Department of Biomedical Engineering and the College of Business at Stony Brook University.
The Professor of Practice will steward the University’s Advanced Graduate Certificate in Life Science Innovation and Entrepreneurship, which was established under Empire State Development’s Life Science Entrepreneur Development award, and further develop educational and experiential learning initiatives. The Director of the Program in Life Sciences Innovation and Entrepreneurship will build upon the Center’s efforts to synergize technology and business accelerator activities with opportunities for students to gain real-world technology commercialization experience.
Prior to joining the Center for Biotechnology and Stony Brook University, Dr. Peña held leadership positions in both industry and academia. He is experienced with startup and early stage companies. Commercializing scientific discoveries he made at Brookhaven National Laboratory, Dr. Peña co-developed a biotech startup that took a biomaterial from idea to clinical trials and acquisition. He later served as Chief Scientific Officer of a biopharma Contract Research Organization. Dr. Peña has also consulted for technology startups in bioagriculture, medical devices, medical imaging, and energy, supporting technology assessment, market assessment, and business strategy.
“We are excited to have Louis join the Center for Biotechnology and Stony Brook University to further our efforts of expanding entrepreneurial education in the life sciences” Diane Fabel, Director of Operations at the Center for Biotechnology said. She continued “His industry involvement, coupled with his academic experiences allow him to bring a unique perspective to the role and for students in our programs to benefit from his real-world experience.”
“I am very happy to join the team at the Center for Biotechnology and my colleagues at Stony Brook University. The Center has a great, established foundation of commercialization and education in this sector and I’m eager to further develop these unique and critical programs” Dr. Peña said. “Our goal is to bolster the life science commercialization knowledge of students graduating from New York universities. At one level, this will help entrepreneurs gain the mix of skills and expertise needed to successfully guide innovative life science startups along the path to commercial viability. At a broader level, this will help with the biotech workforce development of our region and state for those who may not want to start companies but want to understand the sector in great depth so they can secure well-paying and/or leadership positions in this sector.”
Download a PDF of the announcement here.
[post_title] => Dr. Louis A. Peña appointed Director, Program in Life Sciences Innovation and Entrepreneurship & Associate Professor of Practice
[post_excerpt] => Dr. Peña will steward the University’s Advanced Graduate Certificate in Life Science Innovation and Entrepreneurship, and build upon the Center’s efforts to synergize technology and business accelerator activities with opportunities for students.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => dr-louis-a-pena-appointed-director-program-in-life-sciences-innovation-and-entrepreneurship-associate-professor-of-practice
[to_ping] =>
[pinged] =>
[post_modified] => 2023-07-10 12:38:52
[post_modified_gmt] => 2023-07-10 16:38:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4074
[menu_order] => 3
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-26 16:35:20
[post_modified_gmt] => 2025-02-26 21:35:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 270
[max_num_pages] => 90
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
[query_cache_key:WP_Query:private] =>
)
